Our eight finalists come from London, Cambridge and the US and cover the field of therapeutics, diagnostics, medical devices and manufacturing.
Of these eight, up to five winners will be chosen to take part in the second Accelerate@Babraham programme, starting here in September. Find out more about our eight finalists below.
CCBio are harnessing the power of synthetic biology to develop exquisitely specific antimicrobials for the treatment of urogenital/vaginal pathogens, transforming the treatment of infections which affect millions of women worldwide.
MicrofluidX develops a closed, fully scalable automated bioprocessing platform, based on microfluidics, targeted at large-scale advanced therapy manufacturing, in partnership with the Cell and Gene Therapy Catapult and Centre for Process Innovation.
Pregenerate accelerates drug development and personalized medicine for arthritis using our proprietary cartilage on a chip technology to empower better therapies for humans and animals.
QBio are developing a novel molecular diagnostic test and pioneering platform to deliver personalised antibiotics. Faster.
Reflection Therapeutics is creating a first in class treatment for motor neurone disease. We will protect motor neurons from an overactive immune system, prolonging their function and delaying disease progression.
Shift Bioscience is a pre-clinical drug discovery and development company extending healthy lifespan by targeting root causes of aging.
Subcode map and quantitatively measure changes in interaction networks underlying cellular information processing for drug discovery and diagnostics to help cure diseases.
TroMega Therapeutics develops small molecules that change the activity of Tropomyosin4. They change the number of blood platelets and are novel drugs for diseases like Essential Thrombocythaemia and Cardiovascular disease.
Olivia joined SV Health Investors in August 2018 as Principal in the Biotechnology team based in London.
David is Chief Scientific Advisor to Medicxi, while creating new biotech companies, together with Richard Mason, at the Foundation Institute for 21st Century Medicine, based at Babraham Research Campus.
Jane Osbourn is VP R&D at AstraZeneca (formerly MedImmune) with in depth experience of biologics drug discovery and development. She is also Chair of the BioIndustry Association (BIA), the UK trade association for innovative biotech companies.
Dr. Vishal Gulati is a venture partner at Draper Esprit a leading European venture capital firm. His investment interests include healthtech, omics and synthetic biology.
Derek is Chief Executive of Babraham Bioscience Technologies, the company which manages and develops the Babraham Research Campus.
John is leader of AstraZeneca’s Partnering and Strategy group, which focuses on business deals ranging from acquisitions and clinical collaborations to licensing agreements and new industry partnerships.
(+44) 1223 496 000
Babraham Bioscience Technologies Ltd
Babraham Research Campus
CB22 3AT, United Kingdom
01223 813 557